SZU-YEN HUCHIAO-FENG CHENGYang, Kelvin JeasonKelvin JeasonYangCHIH-HSIEN WANGNAI-HSIN CHIRON-BIN HSUYIH-SHARNG CHENHSI-YU YU2022-11-092022-11-092022-09-091569-9293https://scholars.lib.ntu.edu.tw/handle/123456789/624526Systemic lupus erythematosus (SLE) is associated with multi-organ damage including cardiac valve, which may need valvular operation. However, methods for outcome prediction and prosthetic valve selection are unclear in SLE patients undergoing cardiac valve surgery. Twenty-five SLE patients receiving valvular operation in a single institute between 2002 and 2020 were enrolled. Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index (SLICC/ACR damage index, SDI) was applied to evaluate the damage severity. Clinical outcomes were compared between patients with different SDI. The hospital survival rate was 88%, and long-term survival rate was 59.5% and 40.2% at 5 and 10 years. The median SDI was 4 (interquartile range 3-6) in our study, patients were then grouped into higher SDI (defined as SDI ≥ 5, n = 11) and lower SDI group (defined as SDI < 5, n = 14). The in-hospital survival rate (72.2% vs 100%, P = 0.074) and 5-year survival rate (18.2% vs 92.9%, P < 0.001) were lower in higher SDI group, compared to lower SDI group. SDI score was associated with long-term outcome for SLE patients receiving cardiac valve surgery. SDI ≥ 5 was associated with very poor long-term outcomes. This finding implicates that xenograft might be a reasonable choice for SLE patients with SDI ≥ 5.enCardiac valve prosthesesCardiac valvesFollow-up studySystemic lupus erythematosus[SDGs]SDG3journal article10.1093/icvts/ivac221359975712-s2.0-85138458775WOS:000856341300002https://api.elsevier.com/content/abstract/scopus_id/85138458775